Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults

Ray Borrow; Helen Joseph; Nick Andrews; Marisa Acuna; Emma Longworth; Sarah Martin; Nicholas Peake; Rukhsana Rahim; Peter Richmond; Edward Kaczmarski; Elizabeth Miller

doi:10.1016/S0264-410X(00)00317-0

Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults

Ray Borrow^*, Helen Joseph, Nick Andrews, Marisa Acuna, Emma Longworth, Sarah Martin, Nicholas Peake, Rukhsana Rahim, Peter Richmond, Edward Kaczmarski, Elizabeth Miller

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

60 Citations (Scopus)

Abstract

Widespread use of meningococcal A and C polysaccharide (MACP) vaccines has raised concerns about induction of hyporesponsiveness to these polysaccharides. Immunological hyporesponsiveness to C polysaccharide has been clearly documented in infants, children and adults but only limited data from Gambian children are available for A polysaccharide. We investigated whether a second dose of MACP, given 6 months after an initial dose affected the immunological response as measured by the serum bactericidal assay (SBA) and enzyme-linked immunosorbent assay (ELISA), to serogroup A meningococci in young adults (university students, n = 36). Serogroup A SBA responses 1 month following the second dose of MACP (geometric mean titre (GMT) 103.6, 95% CI 45.6-235.1) were approximately one third of the levels observed 1 month post first dose (GMT 281.9, 95% CI 134.9-581.4). The serogroup A-specific IgG levels post second dose (GMC 21.2, 95% CI 15.3-29.4) were also significantly lower at an average of three-quarters the level post first dose (GMC 28.7, 95% CI 20.8-39.7). This confirms that revaccination with MACP vaccine, 6 months following the initial dose, results in a reduced immunological response to A polysaccharide in adults. Repeated vaccination with MACP vaccine may be ineffective and development and use of meningococcal serogroup A conjugate vaccines should be encouraged.

Original language	English
Pages (from-to)	1129-1132
Number of pages	4
Journal	Vaccine
Volume	19
Issue number	9-10
DOIs	https://doi.org/10.1016/S0264-410X(00)00317-0
Publication status	Published - 8 Dec 2000
Externally published	Yes

Bibliographical note

Funding Information:
The laboratory work was supported by Aventis Pasteur. The field work for this study was supported by the UK Department of Health (Grant VCA7/9/3). The authors would like to thank Drs Rosemary McCann and Jenny Hill (Salford and Trafford Health Authority) for their assistance in facilitating the collection of clinical samples.

Keywords

Hyporesponsiveness
Meningococcal serogroup A
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0264-410X(00)00317-0

Cite this

@article{b90397a547794c879bf3472b5fa92e96,

title = "Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults",

abstract = "Widespread use of meningococcal A and C polysaccharide (MACP) vaccines has raised concerns about induction of hyporesponsiveness to these polysaccharides. Immunological hyporesponsiveness to C polysaccharide has been clearly documented in infants, children and adults but only limited data from Gambian children are available for A polysaccharide. We investigated whether a second dose of MACP, given 6 months after an initial dose affected the immunological response as measured by the serum bactericidal assay (SBA) and enzyme-linked immunosorbent assay (ELISA), to serogroup A meningococci in young adults (university students, n = 36). Serogroup A SBA responses 1 month following the second dose of MACP (geometric mean titre (GMT) 103.6, 95% CI 45.6-235.1) were approximately one third of the levels observed 1 month post first dose (GMT 281.9, 95% CI 134.9-581.4). The serogroup A-specific IgG levels post second dose (GMC 21.2, 95% CI 15.3-29.4) were also significantly lower at an average of three-quarters the level post first dose (GMC 28.7, 95% CI 20.8-39.7). This confirms that revaccination with MACP vaccine, 6 months following the initial dose, results in a reduced immunological response to A polysaccharide in adults. Repeated vaccination with MACP vaccine may be ineffective and development and use of meningococcal serogroup A conjugate vaccines should be encouraged.",

keywords = "Hyporesponsiveness, Meningococcal serogroup A, Vaccine",

author = "Ray Borrow and Helen Joseph and Nick Andrews and Marisa Acuna and Emma Longworth and Sarah Martin and Nicholas Peake and Rukhsana Rahim and Peter Richmond and Edward Kaczmarski and Elizabeth Miller",

note = "Funding Information: The laboratory work was supported by Aventis Pasteur. The field work for this study was supported by the UK Department of Health (Grant VCA7/9/3). The authors would like to thank Drs Rosemary McCann and Jenny Hill (Salford and Trafford Health Authority) for their assistance in facilitating the collection of clinical samples. ",

year = "2000",

month = dec,

day = "8",

doi = "10.1016/S0264-410X(00)00317-0",

language = "English",

volume = "19",

pages = "1129--1132",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "9-10",

}

TY - JOUR

T1 - Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults

AU - Borrow, Ray

AU - Joseph, Helen

AU - Andrews, Nick

AU - Acuna, Marisa

AU - Longworth, Emma

AU - Martin, Sarah

AU - Peake, Nicholas

AU - Rahim, Rukhsana

AU - Richmond, Peter

AU - Kaczmarski, Edward

AU - Miller, Elizabeth

N1 - Funding Information: The laboratory work was supported by Aventis Pasteur. The field work for this study was supported by the UK Department of Health (Grant VCA7/9/3). The authors would like to thank Drs Rosemary McCann and Jenny Hill (Salford and Trafford Health Authority) for their assistance in facilitating the collection of clinical samples.

PY - 2000/12/8

Y1 - 2000/12/8

N2 - Widespread use of meningococcal A and C polysaccharide (MACP) vaccines has raised concerns about induction of hyporesponsiveness to these polysaccharides. Immunological hyporesponsiveness to C polysaccharide has been clearly documented in infants, children and adults but only limited data from Gambian children are available for A polysaccharide. We investigated whether a second dose of MACP, given 6 months after an initial dose affected the immunological response as measured by the serum bactericidal assay (SBA) and enzyme-linked immunosorbent assay (ELISA), to serogroup A meningococci in young adults (university students, n = 36). Serogroup A SBA responses 1 month following the second dose of MACP (geometric mean titre (GMT) 103.6, 95% CI 45.6-235.1) were approximately one third of the levels observed 1 month post first dose (GMT 281.9, 95% CI 134.9-581.4). The serogroup A-specific IgG levels post second dose (GMC 21.2, 95% CI 15.3-29.4) were also significantly lower at an average of three-quarters the level post first dose (GMC 28.7, 95% CI 20.8-39.7). This confirms that revaccination with MACP vaccine, 6 months following the initial dose, results in a reduced immunological response to A polysaccharide in adults. Repeated vaccination with MACP vaccine may be ineffective and development and use of meningococcal serogroup A conjugate vaccines should be encouraged.

AB - Widespread use of meningococcal A and C polysaccharide (MACP) vaccines has raised concerns about induction of hyporesponsiveness to these polysaccharides. Immunological hyporesponsiveness to C polysaccharide has been clearly documented in infants, children and adults but only limited data from Gambian children are available for A polysaccharide. We investigated whether a second dose of MACP, given 6 months after an initial dose affected the immunological response as measured by the serum bactericidal assay (SBA) and enzyme-linked immunosorbent assay (ELISA), to serogroup A meningococci in young adults (university students, n = 36). Serogroup A SBA responses 1 month following the second dose of MACP (geometric mean titre (GMT) 103.6, 95% CI 45.6-235.1) were approximately one third of the levels observed 1 month post first dose (GMT 281.9, 95% CI 134.9-581.4). The serogroup A-specific IgG levels post second dose (GMC 21.2, 95% CI 15.3-29.4) were also significantly lower at an average of three-quarters the level post first dose (GMC 28.7, 95% CI 20.8-39.7). This confirms that revaccination with MACP vaccine, 6 months following the initial dose, results in a reduced immunological response to A polysaccharide in adults. Repeated vaccination with MACP vaccine may be ineffective and development and use of meningococcal serogroup A conjugate vaccines should be encouraged.

KW - Hyporesponsiveness

KW - Meningococcal serogroup A

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0034624086&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(00)00317-0

DO - 10.1016/S0264-410X(00)00317-0

M3 - Article

C2 - 11137248

AN - SCOPUS:0034624086

SN - 0264-410X

VL - 19

SP - 1129

EP - 1132

JO - Vaccine

JF - Vaccine

IS - 9-10

ER -

Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this